242 related articles for article (PubMed ID: 35841240)
1. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report.
Delrieu J; Bateman RJ; Touchon J; Sabbagh M; Cummings J
J Prev Alzheimers Dis; 2022; 9(3):393-399. PubMed ID: 35841240
[TBL] [Abstract][Full Text] [Related]
2. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
3. Lecanemab: Appropriate Use Recommendations.
Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
[TBL] [Abstract][Full Text] [Related]
4. [Causal treatment of Alzheimer's disease: amyloid antibodies].
Pawlowski M; Warnecke T
Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
[TBL] [Abstract][Full Text] [Related]
5. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I; Kodama W
Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
[TBL] [Abstract][Full Text] [Related]
7. Donanemab: Not two without a third.
Kurkinen M
Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Terao I; Kodama W
J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
[TBL] [Abstract][Full Text] [Related]
10. ENGAGE and EMERGE: Truth and consequences?
Kuller LH; Lopez OL
Alzheimers Dement; 2021 Apr; 17(4):692-695. PubMed ID: 33656288
[TBL] [Abstract][Full Text] [Related]
11. Critical Appraisal of Amyloid Lowering Agents in AD.
Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
[TBL] [Abstract][Full Text] [Related]
12. Profiling lecanemab as a treatment option for Alzheimer's disease.
Schiller ER; Silverglate BD; Grossberg GT
Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
[TBL] [Abstract][Full Text] [Related]
13. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
Pittock RR; Aakre JA; Castillo AM; Ramanan VK; Kremers WK; Jack CR; Vemuri P; Lowe VJ; Knopman DS; Petersen RC; Graff-Radford J; Vassilaki M
Neurology; 2023 Nov; 101(19):e1837-e1849. PubMed ID: 37586881
[TBL] [Abstract][Full Text] [Related]
14. Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model.
Hao W; Lenhart S; Petrella JR
PLoS Comput Biol; 2022 Sep; 18(9):e1010481. PubMed ID: 36054214
[TBL] [Abstract][Full Text] [Related]
15. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.
Bateman RJ; Cummings J; Schobel S; Salloway S; Vellas B; Boada M; Black SE; Blennow K; Fontoura P; Klein G; Assunção SS; Smith J; Doody RS
Alzheimers Res Ther; 2022 Nov; 14(1):178. PubMed ID: 36447240
[TBL] [Abstract][Full Text] [Related]
16. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.
Aisen PS; Siemers E; Michelson D; Salloway S; Sampaio C; Carrillo MC; Sperling R; Doody R; Scheltens P; Bateman R; Weiner M; Vellas B
J Prev Alzheimers Dis; 2018; 5(3):171-174. PubMed ID: 29972209
[TBL] [Abstract][Full Text] [Related]
17. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
18. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
[TBL] [Abstract][Full Text] [Related]
19. Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.
Boxer AL; Sperling R
Cell; 2023 Oct; 186(22):4757-4772. PubMed ID: 37848035
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
Esquer A; Blanc F; Collongues N
Neurol Ther; 2023 Dec; 12(6):1883-1907. PubMed ID: 37812325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
